Beyond Survival: Targeting Health‐Related Quality of Life Outcomes After Liver Transplantation
David J. Cristin, Lisa M. Forman, Whitney E. Jackson – 3 June 2021
Developing an Evidence Base for the Delivery of Hepatitis B Virus Birth Dose Vaccination: An Evidence Map and Critical Appraisal of Systematic Reviews and Guidelines
Stephanie Doran Brubaker, John W. Ward, Lindsey Hiebert, Rebecca L. Morgan – 3 June 2021
Systemic Therapy for Hepatocellular Carcinoma
Jennifer Wang, Anjana Pillai – 3 June 2021
Killing Two Birds With No Stone
Jane Giang, Dawn S. Harrison, Benjamin K. Hansen, Michael W. Fried, Jama M. Darling – 3 June 2021
Radiation Therapies for the Treatment of Hepatocellular Carcinoma
Neehar D. Parikh, Kyle Cuneo, Mishal Mendiratta‐Lala – 3 June 2021
Classic Autoimmune Liver Disorders and Celiac Hepatitis
Muhammad Amir, Samir M. Parekh – 3 June 2021
Acute Liver Failure Etiology Is an Independent Predictor of Waitlist Outcome but Not Posttransplantation Survival in a National Cohort
Natalie Z. Wong, K. Rajender Reddy, Therese Bittermann – 2 June 2021 – The impact of acute liver failure (ALF) etiology on waitlist (WL) and posttransplantation outcomes, independent of severity of illness, is incompletely characterized. All adults (n = 1691) listed for primary liver transplantation (LT) between 2002 and 2019 with ALF due to acetaminophen toxicity (APAP), drug‐induced liver injury (DILI), autoimmune hepatitis (AIH), and hepatitis B virus (HBV) were identified in the United Network for Organ Sharing database.
Activated CD4+ T Cells and Highly Differentiated Alloreactive CD4+ T Cells Distinguish Operationally Tolerant Liver Transplantation Recipients
Aafke A. Duizendstra, Robert J. Knegt, Shanta Mancham, Mariska Klepper, Dave L. Roelen, Simone H. Brand‐Schaaf, Patrick P. Boor, Michail Doukas, Robert A. Man, Dave Sprengers, Maikel P. Peppelenbosch, Michiel G. H. Betjes, Jaap Kwekkeboom, Nicolle H. R. Litjens – 2 June 2021 – Spontaneous operational tolerance to the allograft develops in a proportion of liver transplantation (LT) recipients weaned off immunosuppressive (IS) drugs.
LiverLearning®: 2021 Webinar: Natural History of NAFLD/NASH in Children: Knowledge, Gaps and Interventions
The gap in natural history data for NAFLD/NASH in children is large, but there have been some significant advances made in the past couple of years. This webinar aims to increase awareness, enhance knowledge and improve health of children with this disorder.Shikha Sundaram Shikha S. Sundaram, MD, FAASLD, is an associate professor of Pediatrics at Children’s Hospital Colorado and the University of Colorado School of Medicine.